Ovagen Peptide: What the Bioregulator Research Shows
Ovagen peptide is a product name for EDL, also coded T-35, a three amino acid peptide (glutamic acid, aspartic acid and leucine). Its research is rat kidney injury studies, kidney cell cultures and computer docking models from one St. Petersburg group, with no human study, no dose, and no peer reviewed paper behind the liver and gut uses sellers list.
Short answer
- What is Ovagen?
- EDL (T-35), sold as Ovagen. Only two reviews use the name Ovagen; every primary paper says EDL or T-35.
- What was it tested on?
- Rats with kidney injury from gentamicin, cisplatin or cut off blood flow, old rats, and kidney cells in a dish.
- Is it a liver peptide?
- Sellers say so. The only source is a review table that cites a patent. No liver study of EDL was found.
Sources: Review, PMC8619776 (2021); Review, PMC9323678 (2022); PubMed 26515176 (2015)
What Sellers Claim vs What the Papers Show
Ovagen is sold as a liver and digestive tract bioregulator, but the research on EDL is about the kidney. The table checks each common claim against the sources found.
| Claim | What backs it | Evidence level |
|---|---|---|
| Kidney protection | Rat injury studies and kidney cell cultures from one research group | Animal and cell data |
| Liver protection | A label in a 2022 review table that cites a patent, not a study. No peer reviewed liver study of EDL was found | No study found |
| Gut or digestive tract support | No source found at all | No study found |
| Anti-aging | Lower aging markers in kidney cells grown in a dish | Cell data only |
| Use in people | No human study on PubMed or ClinicalTrials.gov | None |
Where the name comes from matters here. A 2021 review from the group lists "EDL, Ovagen" for regulating kidney cell function, liver protection and DNA binding. A 2022 review labels Ovagen (EDL) a nephroprotector (kidney protector) and a hepatoprotector (liver protector), and its liver label points to a patent, WO2007139430, rather than a published experiment.
Sources: Review, PMC8619776 (2021); Review, PMC9323678 (2022)
What Is Ovagen Peptide Used For?
No human use of Ovagen is backed by a study. In research, EDL was used to see whether it could protect rat kidneys from injury and slow aging signs in kidney cells.
All of the papers trace back to one research group, the St. Petersburg Institute of Bioregulation and Gerontology led by Khavinson. No other lab has published a test of EDL that was found. For other peptides from the same field, see our guides to vesugen and testagen.
The Rat Kidney Studies
In rats, EDL protected the kidneys in three kinds of injury: from the antibiotic gentamicin, from blood flow being cut off and restored, and from the cancer drug cisplatin. These are animal results.
The 2017 study spells out what improved. EDL prevented low urine output and the build up of nitrogen waste in the blood. It lowered protein and sodium loss in urine, kept antioxidant enzymes from falling to critical levels, held back lipid peroxidation (a kind of cell damage) and normalized energy supply in kidney cells.
The 2015 cisplatin study tested EDL beside two other short peptides, AED and AEDG, and a polypeptide complex taken from kidney tissue. The authors wrote that EDL produced a potent nephroprotective effect.
A 2018 study gave the peptides to old rats. The kidney complex, AED and EDL increased urine output by 1.2 to 1.4 times. The authors say their tissue findings show no nephrotoxic effect, meaning no sign of kidney damage, and that the kidney complex and the peptides AED, EDL and AEDG may be considered nephroprotective agents in kidney aging.
Sources: PubMed 28744634 (2017); PubMed 26515176 (2015); PubMed 30607912 (2018)
The Kidney Cell Studies
In kidney cells grown in a dish, EDL increased cell growth and lowered aging markers. This is where the anti-aging label comes from.
- In young and aged kidney cell cultures, AED and EDL increased cell growth, lowered the aging markers p16, p21 and p53, and raised SIRT-6.
- In kidney tissue cultures from young and old animals, T-31 (AED) and T-35 (EDL) raised cell growth and lowered cell death, but less than the full kidney polypeptide complex did.
- In aging kidney cell cultures, the protein-cutting enzyme MMP-14, a gelatinase, was named as the target of T-35.
Sources: PubMed 25946838 (2014); PubMed 26033601 (2015); PubMed 24958378 (2014)
How EDL Is Said to Work
The group's idea is that very short peptides reach DNA and change which genes are switched on. In their own words, this is a supposition: they suppose short peptides cross the cell and nuclear membranes and bind DNA.
Their computer docking models put AEDL and EDL on the DNA sequence ctcc. A docking model is a computer prediction of where a molecule might fit. It is not a measurement in living cells.
Sources: PubMed 27909961 (2016)
Is There an Ovagen Dose, and How Is It Taken?
No source gives a human dose or a way to take Ovagen. The rat and cell studies found do not define a dose for people, and nothing official explains what product sizes such as Ovagen 20 or Ovagen 50 mean.
For how peptides in general are handled, see our guides on how peptides are taken and oral vs injectable peptides. Neither one is a guide to Ovagen, because there is no Ovagen human data to draw on.
Common Questions
What is ovagen peptide used for?+
There is no human use backed by a study. Ovagen is a product name for EDL (T-35), and the research on EDL is rat kidney injury and kidney cell work. Sellers also list liver and gut uses, but no peer reviewed study of EDL on the liver or gut was found.
What is a peptide and how do you take it?+
A peptide is a short chain of amino acids. EDL, the peptide behind Ovagen, has three: glutamic acid, aspartic acid and leucine. For EDL there is no human study, so no source gives a way to take it or a dose for people.
What is Ovagen 50 used for?+
No source defines Ovagen 50 or Ovagen 20. Those look like product sizes or names set by sellers. No paper gives a human dose or use for any Ovagen product.
Is Ovagen good for the liver?+
That has not been shown. The only source naming a liver effect is a review table that calls Ovagen (EDL) a hepatoprotector and cites a patent for it. No peer reviewed liver study of EDL was found.
Has Ovagen been tested in humans?+
No. PubMed has no human study of Ovagen or EDL, and ClinicalTrials.gov has no Ovagen trial. The results found come from rats, kidney cells in a dish and computer models.
Is Ovagen safe?+
There is no human safety data. One study in old rats reported no signs of kidney damage from EDL, but a rat result does not show safety in people.
Sources: Review, PMC8619776 (2021); Review, PMC9323678 (2022); PubMed 28744634 (2017); PubMed 30607912 (2018)
Related reading
This guide is for educational purposes only and is not medical advice. It describes what published rat, cell and computer studies report about EDL, the peptide sold as Ovagen. Ovagen is a research compound with no approval for human use found. Talk to a qualified healthcare professional before making any decision about your health.